New FDA Approval Expands Use of Cemiplimab in NSCLC

The new approval expands use of the PD-1 inhibitor cemiplimab (Libtayo) to patients with advanced non–small cell lung cancer (NSCLC) irrespective of PD-LI expression.
Medscape Medical News

source https://www.medscape.com/viewarticle/983763?src=rss